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SI Results
Proapoptotic Protein Fragments Examined. Descriptions below are
the more detailed counterparts (with citations of relevant studies)
of the brief descriptions in the text of the 10 previously identiﬁed
proapoptotic C-terminal protein fragments (Cys-RIPK1, Cys-
TRAF1, Asp-BRCA1, Leu-LIMK1, Tyr-NEDD9, Arg-BID, Asp-
BCLXL, Arg-BIMEL, Asp-EPHA4, and Tyr-MET) produced by
caspases (eight fragments) or calpains (two fragments). These
fragments have been shown, in the present work, to be short-
lived substrates of the Arg/N-end rule pathway (Figs. 2–4 and
Figs. S1 and S2). The fragments are cited in the order of their
placements in Figs. 2 and 3. Molecular masses of these proteins
were ∼1 kDa larger than their natural sizes (indicated in Figs. 2
and 3 and below), because the fragments contained the ∼1 kDa
C-terminal ﬂag epitope. The names of proteins are in capital
letters for both human and mouse proteins to make it easy to
distinguish these names from the three-letter notations of N-
terminal residues. The residue numbers of N-terminal residues
in the names of cited fragments are either of mouse or human
versions of these proteins, as indicated, and are identical to
notations in Figs. 2 and 3.
Cys326-RIPK1.RIPK1 is a conditionally short-lived 77-kDa Ser/Thr
kinase and multifunctional regulator of apoptosis, programmed
necrosis (necroptosis), and other processes, including antiviral
responses that do not involve cell death (refs. 1–11 and references
therein). Mouse Cys326-RIPK1 (its human counterpart is Cys325-
RIPK1) is the previously identiﬁed, caspase-generated, proa-
poptotic 41-kDa C-terminal fragment of RIPK1. This fragment
is proapoptotic at least in part through its facilitation of the
activation of caspase-8, which cleaves full-length RIPK1 to
generate more Cys-RIPK1. The result is a positive feedback that
promotes apoptosis (1–3). The previously shown proapoptotic
activity of the Cys-RIPK1 fragment, in the context of circuits that
mediate and regulate other activities of RIPK1 (1–6, 11), re-
mains to be understood in mechanistic detail. The Cys-RIPK1
fragment bears N-terminal Cys, a tertiary destabilizing residue
(Fig. 1A), and it has been shown here to be a short-lived sub-
strate of the Arg/N-end rule pathway (the text, Figs. 2 B and C
and 3K and Figs. S1, S2A, and S3 A and B).
Cys157-TRAF1. TRAF1, in conjunction with RIPK1, TRAF2, and
other TNF receptor-associated proteins, functions to minimize
the activation of caspase-8 and other proapoptotic reactions in
part by contributing to the up-regulation of the antiapoptotic
NF-κB regulon (5, 12). In contrast to full-length TRAF1, its
previously identiﬁed caspase-generated Cys-TRAF1 fragment
(Cys157-TRAF1 in the case of mouse TRAF1) is proapoptotic, at
least in part because it inhibits the activation of NF-κB (12, 13).
The Cys-TRAF1 fragment bears N-terminal Cys, a tertiary de-
stabilizing residue, and has been shown here to be a short-lived
substrate of the Arg/N-end rule pathway (the text, Figs. 2 D and
E and 3L, and Figs. S2B).
Asp1119-BRCA1.Mouse BRCA1 (breast cancer suppressor protein-
1) is a 199-kDa RING-type E3 ubiquitin ligase (human BRCA1 is
a 220-kDa protein) that functions as a tumor suppressor and
participates in DNA repair, cell-cycle checkpoint regulation,
transcriptional control, centrosome function, X-chromosome
inactivation, and other processes as well (refs. 14–16 and refer-
ences therein). Mouse Asp1119-BRCA1 (its human counterpart is
Asp1156-BRCA1) is the previously identiﬁed, caspase-generated,
proapoptotic 78-kDa C-terminal fragment of BRCA1 that bears
N-terminal Asp, a secondary destabilizing residue (Fig. 1A and
Figs. S1 and S2C) (17–19). Ectopic expression of the Asp-
BRCA1 fragment (in contrast to a similar expression of full-
length BRCA1) can either make cells hypersensitive to apoptosis
induced by a variety of agents or cause apoptosis directly, de-
pending on the cell type and conditions of Asp-BRCA1 ex-
pression (17–19). In contrast to full-length BRCA1, which is
largely nuclear under normal conditions, the Asp-BRCA1 frag-
ment is largely cytosolic (19). The mechanism of proapoptotic
activity of the Asp-BRCA1 fragment is unknown. Asp-BRCA1 has
been shown here to be a short-lived substrate of the Arg/N-end
rule pathway (the text, Figs. 2 F and G and 4 C–F, and Fig. S2C).
Leu241-LIMK1.Human LIMK1 (LIM kinase-1) is a 73-kDa Ser/Thr
kinase that functions, in particular, as a downstream effector of
ρ-signaling pathways and regulator of actin dynamic. Among
phosphorylation targets of LIMK1 are actin-binding proteins
such as coﬁlin (refs. 20–22 and references therein). Leu241-
LIMK1 is the previously identiﬁed, caspase-generated, 48-kDa
proapoptotic C-terminal fragment of human LIMK1 that con-
tains the active kinase domain and lacks the N-terminal auto-
inhibitory domain (21). Although it is likely that the proapoptotic
activity of the Leu-LIMK1 fragment stems from its increased
kinase activity, compared with full-length LIMK1 (21), detailed
understanding of proapoptotic effects of Leu-LIMK1 remains to
be attained. The Leu-LIMK1 fragment bears N-terminal Leu,
a primary destabilizing residue (Fig. 1A), and it has been showed
here to be a short-lived substrate of the Arg/N-end rule pathway
(the text, Figs. 2 H and I, and Figs. S1 and S2F).
Tyr631-NEDD9. Human NEDD9 (neural precursor cell-expressed,
developmentally down-regulated 9; one of its other names is
human enhancer of ﬁlamentation 1) is a 93-kDa scaffolding
protein with functions that include cell attachment, migration,
and mitotic control. NEDD9 is frequently overexpressed in hu-
man cancers, including glioblastomas and breast cancers. NEDD9
is a member of the Cas family that also includes p130CAS and
EFS/SIN (refs. 23–27 and references therein). Human Tyr631-
NEDD9 is the previously identiﬁed, caspase-generated, proa-
poptotic 24-kDa C-terminal fragment of NEDD9 (23–25). De-
tailed understanding of proapoptotic effects of Tyr-NEDD9
remains to be attained. The Tyr-NEDD9 fragment is produced
largely (possibly exclusively) during apoptosis, bears N-terminal
Tyr (a primary destabilizing residue), and has been shown here
to be a short-lived substrate of the Arg/N-end rule pathway (the
text, Figs. 1A and 2 J and K, and Figs. S1 and S2E).
Arg71-BID.HumanBID is a 22-kDamember of the BCL-2 family of
proteins that regulates the permeabilization of the outer mito-
chondrial membrane, a step that leads to the release of cyto-
chrome c into the cytosol and thereby, initiates apoptosis (5, 28,
29). Although full-length BID is a proapoptotic regulator, its
C-terminal fragments, which can be naturally produced by acti-
vated caspases, calpains, granzyme B, or cathepsins, can be even
more active than intact BID as proapoptotic proteins (30). The
cleavage of human BID by activated calpain-1 produces the
14-kDa Arg71-BID proapoptotic fragment (30–33) that has been
shown here to be a short-lived substrate of the Arg/N-end rule
pathway (Figs. 1A and 3 A and B and Figs. S1 and S2D). (The
cleavages of BID by caspases produce C-terminal fragments that
bear either N-terminal Gly or N-terminal Ser [i.e., the residues
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that are not recognized by the Arg/N-end rule pathway (29, 30)].)
BID is cleaved by activated calpains during cell death that is
induced by cisplatin (a DNA-damaging agent), under conditions
that cause endoplasmic reticulum (ER) stress, or in cardiomyocytes
during ischemia/reperfusion (30–33). Speciﬁc reasons for the ob-
served higher proapoptotic activity of the Arg-BID fragment com-
pared with full-length BID are unknown.
Asp61-BCLXL. Mouse BCLXL is a 26-kDa antiapoptotic regulatory
protein (5, 34). Under conditions that include glucose and oxy-
gen deprivation of mammalian cells, BCLXL can be cleaved by
activated calpain-1, resulting in the 21-kDa Asp61-BCLXL frag-
ment that has proapoptotic activity in contrast to full-length
BCLXL (35). The mechanism of proapoptotic activity of the Asp-
BCLXL fragment is unknown. Asp-BCLXL bears N-terminal Asp,
a secondary destabilizing residue, and it has been shown here to
be a short-lived substrate of the Arg/N-end rule pathway (the
text, Figs. 1A and 3 C and D, and Figs. S1 and S2G).
Arg14-BIMEL. Isoforms of BIM (BIMEL, BIML, and BIMS), pro-
duced by alternative splicing of BIM pre-mRNA, are members of
the Bcl-2 family of apoptosis regulators that control, in partic-
ular, the mitochondrial permeability transition that results in the
release of cytochrome c and downstream proapoptotic steps (5).
A major function of BIM proteins is to promote the initiation of
apoptosis through interactions with mitochondria-associated
antiapoptotic Bcl-2–type proteins. Activity of the BIM gene plays
a role in the development of B and T lymphocytes, and it is
required for the physiologically relevant apoptosis of activated T
lymphocytes (5, 36, 37). BIMEL, a 22 kDa protein, is the major
isoform of BIM in T cells. It has been shown that human BIMEL
is cleaved by caspase-3 or other caspases during apoptosis, re-
sulting in the 21-kDa Arg14-BIMEL fragment. The proapoptotic
activity of Arg14-BIMEL is considerably higher than the activity
of uncleaved BIMEL (37). In unperturbed cells, a large fraction
of BIMEL dynamically interacts with tubulin of the microtubules,
in contrast to BIML and BIMS, which do not interact with tu-
bulin. Unphosphorylated BIMEL binds to microtubules, whereas
phosphorylated BIMEL has a much lower afﬁnity for them. The
tubulin-associated BIMEL is prevented from exerting proa-
poptotic effects on prosurvival members of the Bcl-2 protein
family. During the initiation of apoptosis, BIMEL that dis-
sociates from microtubules is cleaved by caspase-3 or other
caspases at the Asp13-Arg14 peptide bond. The resulting Arg14-
BIMEL fragment has a higher afﬁnity for the prosurvival Bcl-2
protein than the uncleaved, full-length BIMEL, thus accounting,
at least in part, for the higher proapoptotic activity of caspase-
processed Arg14-BIMEL (37). The Arg-BIMEL fragment bears N-
terminal Arg, a primary destabilizing residue, and has been
shown here to be a short-lived substrate of the Arg/N-end rule
pathway (the text, Figs. 1A and 3 E and F, and Fig. S2H).
Asp774-EPHA4. Mouse EPHA4 (ephrin receptor A4) is a 110-kDa
transmembrane receptor for its ligand EPHRINB3. EPHA4 is
a member of the family of more than 10 mammalian dependence
receptors (DpRs) (refs. 38–45 and references therein). These
DpR receptors are usually not related by sequence or structure
but are functionally analogous because of their ability to mediate
two opposite physiological outcomes. In the presence of its
cognate ligand, a DpR receptor activates signaling pathways that
mediate cell survival, migration, proliferation, or differentiation.
In the absence of its ligand, a DpR produces a proapoptotic
signal, often through the formation, by caspases or other non-
processive proteases, of a C-terminal proapoptotic fragment that
functions in the cytosol and/or the nucleus (38–44). Among the
functions of the uncleaved, full-length EPHA4 (in the presence
of its cognate ligand EPHRINB3) are the promotion and regu-
lation of neurogenesis. In the absence of EPHRINB3, the in-
tracellular domain of EPHA4 is cleaved by caspase-3 or related
caspases, generating the proapoptotic Asp774-EPHA4 fragment
(42, 45). The mechanism of proapoptotic activity of the Asp-
EPHA4 fragment is unknown. This 24-kDa fragment bears N-
terminal Asp, a secondary destabilizing residue, and it has been
shown here to be a short-lived substrate of the Arg/N-end rule
pathway (the text, Figs. 1A and 3 G and H, and Figs. S1 and S2I).
Tyr1001-MET. The mouse transmembrane receptor MET (its other
name is hepatocyte growth factor receptor) is the second de-
pendence receptor (other than EPHA4) examined in the present
work.MET is a 154-kDa receptor tyrosine kinase with functions in
embryonic development and organ formation (refs. 38–42 and
46–50 and references therein). In the absence of its cognate li-
gand, such as the 80-kDa hepatocyte growth factor, the in-
tracellular domain of MET is cleaved by caspase-3 or related
caspases, generating the proapoptotic 43-kDa Tyr1001-MET
fragment [∼42 kDa if one takes into account a cleavage at the
second, C terminus-proximal caspase cleavage site in mouse
MET at Asp1374-Gly1375, ﬁve residues upstream of the last
(Thr1379) residue of MET] (42, 45, 48–50). The mechanism of
proapoptotic activity of Tyr-MET is unknown. The Tyr-MET
fragment bears N-terminal Tyr, a secondary destabilizing resi-
due, and it has been shown here to be a short-lived substrate of
the Arg/N-end rule pathway (the text, Figs. 1A and 3 I and J, and
Figs. S1 and S2J).
SI Materials and Methods
Miscellaneous Reagents. Cycloheximide and tamoxifen were from
Sigma.Mouse and human cDNAs were fromOpenBiosystems. Z-
DEVD-FMK and Z-VAD-FMK were from Enzo Life Sciences.
The following antibodies were used: anti-FLAG M2 (F1804;
Sigma), anti-HA (H3663; Sigma); anti-RIPK1 (a monoclonal an-
tibody to a C-terminal region of human RIPK1 that cross-reacts
with mouseRipk1; 610458; BDBiosciences); anticaspase-3 (9662S;
Cell Signaling); anti-BRCA1 (I-20, Sc-646; Santa Cruz); afﬁnity-
puriﬁed polyclonal antibody to mouse ATE1 (51); and afﬁnity-
puriﬁed polyclonal antibody to mouse UBR1 (52). The latter
antibody was used as a 1:1 mixture of afﬁnity-puriﬁed polyclonal
antibodies to the synthetic peptides EMDPDLEKQEESVQ
(UBR1 residues 54–67) and HEPGRAGTTKESLH (UBR1 res-
idues 166–179), respectively (52). Clean-Blot IP Detection Re-
agent was from Thermo Scientiﬁc (21210). The following reagents
were used for immunoprecipitation: anti-FLAG M2 Magnetic
Beads (M8823; Sigma), Protein A/G Magnetic Beads (88802;
Pierce), and EZview Red anti-HA afﬁnity gel (E6779; Sigma).
Recombinant human TNFα was from R&D, Inc. (210-TA) and
Shenandoah Biotechnology, Inc. (100-111). Recombinant active
human caspase-8 was from Cayman Chemical.
Animal Care and Treatments. All animal care and procedures were
carried out according to the relevant National Institutes of Health
guidelines, and they were approved (protocol #1328) by the
Institutional Animal Care and Use Committee and the Ofﬁce of
Laboratory Animal Research at the California Institute of
Technology, where the present study was performed. Mice were
housed at ∼22 °C using a 12 h light to 12 h dark cycle, with
Laboratory Rodent Diet 5001 (PMI International) ad libitum. In
conditionally ATE1-deﬁcient Ate1ﬂox/-; CaggCreER mice, one
copy of Ate1 was inactive, whereas the other (ﬂoxed) copy of
Ate1 could be inactivated in adult mice through a transient ac-
tivation of Cre recombinase, which was expressed from the
ubiquitously active chimeric Cagg promoter and transiently ac-
tivated by tamoxifen (53). ATE1-containing mice were Ate1ﬂox/+
and lacked Cre. Ate1ﬂox/-; CaggCreER and Ate1ﬂox/+ mice be-
tween 3 and 8 wk of age were treated with tamoxifen (2 mg in 0.2
mL sesame oil) by daily i.p. injections over 5 d (53); 3 wk after
tamoxifen treatment (53), TNFα (50 μg/kg) was administered by
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tail vein injection. Speciﬁc tissues were harvested and analyzed
by immunoblotting 12 h after TNFα injection.
Plasmids, cDNAs, and Primers. DH5α Escherichia coli (Invitrogen)
was used for cloning and maintaining plasmids. Phusion High-
Fidelity DNA polymerase (New England Biolabs) was used for
PCR. Sequences of all constructed plasmids were veriﬁed by
DNA sequencing. The plasmid pKP496 was constructed by li-
gation of annealed primers 1,447 and 1,448 into SacII/XbaI-cut
pcDNA3fDHFRUbR48Xpr (54). The resulting plasmid, which
encoded the fDHFR-UbK48R-MCS (SacII-EcoRI-XhoI-ClaI-
EcoRV)-ﬂag fusion, was used to construct plasmids for the
ubiquitin reference technique (55).
RIPK1. The human RIPK1 ORF was ampliﬁed from a human
HeLa cDNA library using primers 652, 653, and 647 (Table S2)
that encoded a C-terminal ha2-ﬂag epitope. The resulting DNA
fragment was inserted into pcDNA3-Neo (Invitrogen) using
HindIII/XhoI sites. A plasmid expressing mouse Ripk1 cDNA
was produced similarly using a cDNA library from C57BL/6 mice
and primers 650, 651, and 647 (Table S2). The plasmids pKP395,
pKP396, and pKP397, which expressed ﬂag-DHFR-Ub-X-
RIPK1-ﬂag fusions (X = Cys, Asp, Val; mouse RIPK1) were
constructed by amplifying the mouse RIPK1-encoding DNA
fragment with the following sets of primers: 702, 697, and 706
(Cys326-RIPK1); 703, 697, and 706 (Asp326-RIPK1); and 705,
697, and 706 (Val326-RIPK1). The resulting fragments were di-
gested with SmaI and XbaI and were cloned into SfoI/XbaI-cut
pcDNA3fDHFRUbR48Xpr (54). The pcDNA5/FRT/TO plas-
mid (Invitrogen) containing a tetracycline-regulated, hybrid
human cytomegalovirus CMV/TetO2 promoter was used to
construct the plasmids pcDNA5/TO/Ub-X325-RIPK1, which en-
coded UbR48-X325-RIPKf (human RIPK1); x was a variable
residue at the Ub–protein junction (55). These plasmids were
constructed by ligating PCR-produced DNA fragments to XhoI/
XbaI-cut pcDNA5/FRT/TO.
TRAF1. The mouse Traf1 ORF was ampliﬁed using cDNA from
OpenBiosystems (30748947) and primers 1,188 and 1,189. The
resulting fragment was cut with BamHI and XbaI and cloned
into BamHI/XbaI-cut pcDNA3.0 (Invitrogen), generating the
plasmid pKP378. The ORF of mouse Traf1 containing the
D156A point mutation was ampliﬁed using primers 1,188, 1,190,
1,191, 1,189, and pKP378 (Table S2) as a template. The resulting
fragment was cut with BamHI and XbaI and cloned into BamHI/
XbaI-cut pcDNA3.0 (Invitrogen), generating the plasmid pKP379.
The plasmids pKP380, pKP381, and pKP382, which expressed
ﬂag-Ub-X157-TRAFf fusions (X = Cys, Asp, Val; mouse Traf1),
were constructed by amplifying the mouse TRAF1-encoding
DNA fragment with the following sets of primers: 1,192 and
1,189 (Cys157-TRAF1); 1,195 and 1,189 (Asp157-TRAF1); and
1,196 and 1,189 (Val157-TRAF1). The resulting fragments
were linked to DNA encoding ﬂag-tagged Ub (constructed by
PCR ampliﬁcation using primers 1,197, 1,198, 1,194, and the
pcDNA3fDHFRUbR48Xpr plasmid as a template) using pri-
mers 1,197 and 1,189. The resulting DNA fragment was cut with
BamHI and XbaI and cloned into BamHI/XbaI-cut
pcDNA3fDHFRUbR48Xpr (54).
BRCA1. The mouse Brca1 ORF was ampliﬁed using cDNA from
OpenBiosystems (30431022) and primers 1,438 and 1,440 for
Asp1119-BRCA1 or 1,439 and 1,440 (Table S2) for Val1119-
BRCA1. The resulting DNA fragments were cut with SacII and
ClaI and cloned into SacII/ClaI-cut pKP496, generating the
plasmids pKP528 and pKP529, respectively.
LIMK1. The human LIMK1 ORF was ampliﬁed using cDNA from
OpenBiosystems (LIFESEQ95191844) and primers 1,467 and
1,469 for Leu241-LIMK1 or 1,468 and 1,469 for Val241-LIMK1.
The resulting fragments were cut with SacII and ClaI and cloned
into SacII/ClaI-cut pKP496, generating the plasmids pKP512
and pKP513, respectively.
NEDD9. The human NEDD9 ORF was ampliﬁed using cDNA
from OpenBiosystems (6299616) and primers 1,479 and 1,481
for Tyr631-NEDD9 or 1,480 and 1,481 for Val631-NEDD9. The
resulting fragments were cut with SacII and ClaI and cloned into
SacII/ClaI-cut pKP496, generating the plasmids pKP526 and
pKP527, respectively.
BID. The human BIDORF was ampliﬁed using cDNA from Open-
Biosystems (5179075) and primers 1,473 and 1,475 for Arg71-BID
or 1,474 and 1,475 Val71-BID. The resulting fragments were di-
gested with SacII and ClaI and cloned into SacII/ClaI-cut pKP496,
generating the plasmids pKP523 and pKP524, respectively.
BCLXL. The mouse BclXL ORF was ampliﬁed using cDNA from
OpenBiosystems (6830063) and primers 1,432 and 1,434 for
Asp61-BCLXL or 1,433 and 1,434 for Val
61-BCLXL. The resulting
fragments were cut with SacII and ClaI and cloned into SacII/
ClaI-cut pKP496, generating the plasmids pKP514 and pKP515,
respectively.
BIMEL. The mouse BimEL ORF was ampliﬁed using cDNA from
OpenBiosystems (4459720) and primers 1,435 and 1,437 for
Arg14-BIMEL or 1,436 and 1,437 for Val
14-BIMEL. The resulting
fragments were cut with SacII and ClaI and cloned into SacII/
ClaI-cut pKP496, generating the plasmids pKP521 and pKP522,
respectively.
EPHA4. The mouse EphA4 ORF was ampliﬁed using cDNA from
OpenBiosystems (IMAGE 6512978) and primers 1,369 and 1,371
for Asp774-EPHA4 or 1,427 and 1,428 for Val774-mEPHA4. The
resulting fragments were cut with SmaI and XbaI and cloned into
SfoI/XbaI-cut pcDNA3fDHFRUbR48Xpr, generating the plas-
mids pKP492 and pKP493, respectively.
MET. The mouse MET was ampliﬁed using cDNA from Open-
Biosystems (IMAGE 40098362) and primers 1,426 and 1,428
for Tyr1001-MET or 1,427 and 1,428 for Val1001-MET. The
resulting fragments were cut with SacII and ClaI and cloned
into SacII/ClaI-cut pKP496, generating the plasmids pKP519
and pKP520, respectively.
Tissue Extracts and Immunoblotting. Mouse tissues were processed
in Triton lysis buffer (1% Triton X-100, 50 mM NaCl, 2 mM
EDTA, 50 mM Tris·HCl, pH 7.4) containing complete protease
inhibitor cocktail (Roche) using the MP FastPrep-24 instrument
and Lysing Matrix D (MP Biomedicals), with three runs at 6.5
m/s for 20 s each and 5-min incubations on ice between the runs.
The extracts were centrifuged at 10,000 × g for 10 min at 4 °C.
Total protein concentrations in the supernatants were de-
termined using the BCA assay (Pierce), followed by the addition
of a concentrated SDS sample buffer (to the ﬁnal concentration
of 1× SDS sample buffer), heating at 95 °C for 10 min, and SDS
4–15% PAGE, with 100 μg total protein per lane. Fractionated
proteins were analyzed by immunoblotting (including electro-
blotting to Immobilon-P PVDF membranes; Millipore) using
antibodies indicated. Immunoblots were visualized using Super-
Signal West Pico or SuperSignal West Femto reagents (Thermo
Scientiﬁc) or ECL Plus Western blotting Detection System (GE
Healthcare) according to manufacturer’s instructions.
TUNEL Assays with Mouse Tissues. Recombinant human TNFα (50
μg/kg body weight) dissolved in PBS containing 0.2% BSA was
injected into the tail vein of ∼2-mo-old mice 3 wk after tamox-
Piatkov et al. www.pnas.org/cgi/content/short/1207786109 3 of 15
ifen treatment to induce ablation of the ﬂoxed Ate1 gene (in the
text and ref. 53); 12 h after TNFα injection, mice were anes-
thetized by an i.p. injection of Na-pentobarbital (40 mg/kg;
Nembutal; Abbott Laboratories), and their organs were ﬁxed
with 4% formaldehyde in PBS by cardiac perfusion. Thereafter,
speciﬁc tissues were removed and embedded with parafﬁn using
standard procedures. After sectioning into 10-μm sections, tis-
sues were assayed using the ﬂuorescein-based In Situ Cell Death
Detection Kit (Roche) according to the manufacturer’s protocol.
The sections were then counterstained with DAPI and analyzed
by ﬂuorescence microscopy using a Zeiss Axiophot microscope.
Cell Cultures and Apoptosis Assays. The mouse NIH-3T3 cell line
was from American Type Culture Collection and grown in the
DMEM supplemented with 10% FBS (Gibco) and penicillin/
streptomycin (100 units/mL; HyClone). Human Flp-In T-REx-
293 cells (Invitrogen) were grown similarly, but DMEM was
supplemented with tetracycline-free 10% FBS (Tet-free FBS;
Clontech). T-REx-293–based human cell lines expressing Ub-X-
RIPK1 fusions (X=Cys, Asp, Val; in the text) from a doxycycline
(Dox) -inducible promoter were produced using an Flp re-
combinase-mediated integration system in these cells (In-
vitrogen). Brieﬂy, pcDNA5/FRT/TO (vector alone), pKP418,
pKP419, or pKP420 (Table S1) were cotransfected with pOG44
(transiently expressing Flp recombinase) into T-REx-293 cells
using Lipofectamine-2000 (Invitrogen); 48 h posttransfection,
each transfected cell culture was split in one-half and plated in the
presence of hygromycin B (100 μg/mL; Invitrogen). After 2–3 wk,
individual cell colonies were isolated and analyzed by immuno-
blotting to detect a Dox-dependent expression of a transgene.
Untransformed primary (precrisis) mouse embryonic ﬁbro-
blasts (EFs) were prepared using previously described techniques
(56). These primary EFs were derived from the previously de-
scribed ATE1-containing Ate1ﬂox/-, CreER E15 embryos that
were heterozygous at the Ate1 locus (53). Two recently and
equally split cultures of Ate1ﬂox/-, CreER primary EF cells were
treated daily with either 50 nM tamoxifen in DMSO (to ablate
the ﬂoxed Ate1 allele) or DMSO alone for 5 consecutive d. Both
control and experimental cultures were grown in the absence of
DMSO/tamoxifen for an additional 7 d. Thereafter, the cultures
were treated for 24 h with increasing concentrations of TNFα
(between 0 and 25 ng/mL) in DMEM that also contained 0.5%
FBS and a nontoxic (2.5 μg/mL) concentration of cycloheximide.
In most experiments, 106 cells/well were treated in a 24-well
plate for indicated times. Cells were then washed on a plate one
time with PBS, lysed in 1% SDS supplemented with protease
inhibitors, and heated at 95 °C for 5 min. Protein concentration
in the samples was determined using the BCA assay (Pierce).
One volume of 2× SDS sample buffer was added, the resulting
samples were heated at 95 °C for 5 min, and 50 μg protein per
lane were fractionated by SDS 4–15% PAGE, followed by im-
munoblotting with a monoclonal antibody to a C-terminal region
of RIPK1 or an afﬁnity-puriﬁed antibody to mouse ATE1. All
immunoblots were also analyzed for sample-loading uniformity
using antitubulin antibody as well as staining of proteins with
Coomassie-R250.
Colony-formation assays were carried out with WT, Ate1−/−,
and Ubr1−/− Ubr2−/− double-mutant EF cell lines. These EF cell
lines were produced and characterized previously (52, 57–59).
For experiments in the present study, we used Ubr1−/− Ubr2−/−
EFs (58, 59) and also, an Ate1−/− EF cell line (as well as its WT
EF counterpart) that was produced using previously described
methods (57) but independently and speciﬁcally in the present
work using E13.5 Ate1−/− embryos and their WT littermates.
For TUNEL analysis of EF cell lines or primary (precrisis) EF
cells in culture, cells were grown in DMEM (Gibco) supple-
mented with 10% FBS, standard antibiotics, and 2 mM L-glu-
tamine. Cells were plated at ∼0.5 × 105 cells per 22-mm well on
coverslips coated with poly-L-lysine. After 12 h, cells were trea-
ted with increasing concentrations of staurosporine (between
0 and 1 μM) for 24 h or speciﬁed doses of ∼260 nm UV irra-
diation followed by ﬁxation in 4% formaldehyde. Cells were then
analyzed using TUNEL as described above.
Assay for Activated Caspase-3.Caspase activity was measured using
the ﬂuorogenic substrate Ac-DEVD-AMC (Caspase-3 Assay Kit;
Pharmingen) according to the manufacturer’s protocol. Brieﬂy,
T-Rex-293–based cell cultures, at 80–90% conﬂuence, were
treated with trypsin to detach the cells and stained with Trypan
Blue (to measure the percentage of dead cells); total cell num-
bers were determined using a hemocytometer. Cells were seeded
into a 96-well plate with 104 cells/well containing 0.1 mL DMEM
and 10% FBS, and they were incubated for 24 h with increasing
concentrations of Dox. Then, cells were incubated for another
12 h with cycloheximide (at its nontoxic concentration of 2.5 μg/
mL). Thereafter, the medium was removed, and cells were
washed one time with PBS; 30 μL buffer A (10 mM KCl, 1.5 mM
MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM PMSF,
20 mM Hepes, pH 7.2) containing complete protease-inhibitor
mixture (Roche) were added to each well, and the plate was
incubated on ice for 20 min followed by breaking the cells
through three cycles of freezing in liquid N2 and thawing the
samples at 37 °C in a water bath. The resulting samples were
centrifuged at 3,000 × g for 30 min. Protein concentrations in the
supernatants were determined using Coomassie Plus Protein
Assay (Pierce). Centrifugation-clariﬁed extracts (20 μg total
protein) were incubated with 5 μg Ac-DEVD-AMC, a ﬂuoro-
genic caspase-3 substrate, in the total volume of 0.2 mL at 37 °C
for 1 h followed by measurements of ﬂuorescence in a microplate
ﬂuorimeter using 380-nm excitation and 430-nm emission ﬁlters.
In Vitro Caspase Assays with ATE1 and UBR1. Puriﬁed Ate11B7A
isoform of theAte1R-transferase (60, 61) or an extract fromNIH-
3T3 cells was incubated with active recombinant human caspase-8
followed by SDS 4–12% PAGE and immunoblotting with afﬁnity-
puriﬁed antibodies to mouse ATE1 or mouse UBR1.
In Vitro Transcription–Translation–Degradation Assay. The TNT T7
Coupled Transcription/Translation System, a version of the
Promega rabbit reticulocyte extract preparation in which themain
components of the system were supplied separately, was used to
carry out transcription–translation–degradation assays. Reaction
samples were prepared according to the manufacturer’s in-
structions. Newly formed proteins in reticulocyte extract were
pulse-labeled with L-[35S]methionine (0.55 mCi/mL, 1,000 Ci/
mmol; MP Biomedicals) for 5 min in total volume of 30 μL. The
labeling was quenched by the addition of cycloheximide and
unlabeled methionine to the ﬁnal concentrations of 0.1 mg/mL
and 5 mM, respectively. Unless stated otherwise, the reactions
were carried out at 30 °C and terminated by the addition of an
equal volume of TDS (Tris-dodecyl-sulfate) buffer (1% SDS,
5 mM DTT, 50 mM Tris·HCl, pH 7.4, also containing complete
protease-inhibitor mixture; Roche) followed by heating at 95 °C
for 10 min. The resulting samples were diluted with 10 volumes
of TNN (Tris-Nonidet-NaCl) buffer (0.5% Nonidet P-40, 0.25 M
NaCl, 5 mM EDTA, 50 mM Tris·HCl, pH 7.4, also containing
complete protease-inhibitor mixture; Roche), and the amounts of
35S in the 10% CCl3COOH-insoluble fraction were measured. For
immunoprecipitation, samples were adjusted to contain equal
amounts of total 35S and were added to 10 μL beads with an im-
mobilized antibody, either antiﬂag or antiha (see above). The
samples were incubated with rocking at 4 °C for 4 h, followed by
four washes in TNN buffer, resuspension in 20 μL SDS sample
buffer, and heating at 95 °C for 10 min followed by SDS 4–15%
PAGE and autoradiography. Quantiﬁcation of autoradiograms
was carried out using PhosphorImager (Molecular Dynamics).
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Alternatively, the samples (not labeled with 35S) were analyzed
using immunoblotting with indicated antibodies.
In Vitro Arginylation Assay.The arginyl-transferase (R-transferase)
assay (20 μL) contained an extract from NIH 3T3 cells (4 mg/mL
total protein), α-lactalbumin (arginylation reporter; 1.25 mg/mL)
(60), total E. coli tRNA (0.6 mg/mL; Sigma), total E. coli ami-
noacyl-tRNA synthetases (800 U/mL; Sigma), 5 μM MG132
(proteasome inhibitor; Sigma), 2 mM ATP, 0.15 M KCl, 10 mM
MgCl2, 1 mM DTT, 50 mM Tris·HCl (pH 8.0), 10 mM phos-
phocreatine, creatine kinase (20 μg/mL; Sigma), 2 μM Arg, and
0.3 μM L-3H-arginine (PerkinElmer). The reaction mixture was
incubated for 60 min at 30 °C and deposited onto Whatman
3MM ﬁlter disks (GE Healthcare). The ﬁlters were incubated for
10 min in 10% cold CCl3COOH, followed by 10 min in 10%
CCl3COOH at 95 °C. The ﬁlters were then washed in 5%
CCl3COOH three times at room temperature followed by a sin-
gle diethyl ether-ethanol (1:1) wash, two diethyl ether washes,
and measurements of 3H retained on a ﬁlter using a scintillation
spectrometer. The R-transferase assay for ATE1 that had been
treated with caspase-8 was performed identically, except that
L-14C-arginine was used. The reaction mixture was incubated for
60 min at 30 °C. The reaction was terminated by the addition of
an equal volume of 2× SDS sample buffer and heating at 95 °C
for 10 min, followed by SDS 4–15% PAGE and autoradiography.
Antibody Speciﬁc for Arg-Asp1119-BRCA1, the Nt-Arginylated
Asp1119-BRCA1 Fragment. Rabbit peptide-mediated antibody to
RDVEIQGHTSFC, theNt-arginylatedN-terminal sequence of the
Asp1119-BRCA1 fragment (except for C-terminal Cys, which was
used to conjugate the peptide to a carrier protein) was produced by
Abgent using standard methods. The peptides RDVEIQGHTSFC
and its nonarginylated counterpart DVEIQGHTSFC were syn-
thesized and puriﬁed also by Abgent. The resulting antibody
was afﬁnity-puriﬁed at ﬁrst positively against the immobilized
RDVEIQGHTSFC peptide using standard methods (62). The
peptide-bound antibody fraction was eluted and saved. This frac-
tion was thereafter negatively puriﬁed against the immobilized
DVEIQGHTSFC peptide. The unbound fraction, used as the an-
tibody to the Nt-arginylated Arg-Asp1119-BRCA1 fragment (Fig.
4E), was strikingly speciﬁc for theRDVEIQGHTSFCpeptide (Fig.
4B). Immunoblotting was carried out (with the antibody at 0.3 μg/
mL) for 8 h at room temperature in 5% skim milk in TBS con-
taining 0.1% Tween-20. The bound antibody was detected using
the Chemiluminescent Kit (ECL Plus; GE Healthcare Life Scien-
ces) and a goat anti-rabbit antibody (at 1:2,000 dilution) conjugated
to HRP.
Pulse-Chase Assay with Endogenous BRCA1. Mouse EF cell lines
were grown in DMEM (Gibco) supplemented with 10% FBS,
standard antibiotics, and 2 mM L-glutamine. Cells were plated at
∼70% conﬂuence in 10-cm plates (one plate per each time
point). After 12 h, cells were treated with UV irradiation (∼260
nm and 60 J/m2), followed by incubation for 4 h and the labeling
of cells with [35S]methionine/cysteine (1 mCi per plate) for 60
min in DMEM without methionine (Sigma). Caspase inhibitors
Z-DEVD-FMK (3 μM) and Z-VAD-FMK (100 μM; a pan-cas-
pase inhibitor) as well as unlabeled methionine and cysteine (to
2 mM) were then added followed by a chase for 1 and 2 h. Plates
were washed two times with 1× PBS, and cells were lysed by
adding 1 mL TDS0.1 buffer (0.1% SDS, 5 mM DTT, 50 mM
Tris·HCl, pH 7.4, also containing complete protease-inhibitor
mixture; Roche) followed by heating at 95 °C for 10 min. The
resulting samples were diluted with 10 volumes TNN0.25 buffer
(0.25% Nonidet P-40, 0.125 M NaCl, 5 mM EDTA, 50 mM
Tris·HCl, pH 7.4, also containing complete protease-inhibitor
mixture), and the amounts of 35S in the 10% CCl3COOH-in-
soluble fraction of each sample were determined. For immuno-
precipitation, samples were adjusted to contain equal amounts of
total 35S (∼1 × 108 cpm) and were added to 40 μL anti-BRCA1
antibody (I-20; Santa Cruz). The samples were incubated with
rocking at 4 °C for 4 h. Protein A/G Magnetic Beads (Pierce)
were then added followed by additional incubation for 1 h at 4 °C.
Beads were collected followed by four washes in TNN buffer,
resuspension in 20 μL SDS sample buffer, and heating at 95 °C
for 10 min, which was followed by SDS 4–12% PAGE and au-
toradiography. Quantiﬁcation of autoradiograms was carried out
using PhosphorImager (Molecular Dynamics).
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Protein Cleavage site
Proapoptotic protein fragments that are experimentally confirmed N-end rule substrates
Proapoptotic protein fragments that remain to be verified as N-end rule substrates
C-terminal fragmentNt-residue
Nd t
Nd t
Ndp
Proapoptotic fragment, generated by caspase-8, of the RIPK1 
kinase. Cys-RIPK1 is an N-end rule substrate.
Nds
Proapoptotic fragment, generated by caspase-3, of the antiapoptotic  
protein kinase Cδ. Asn-PKCδ is a likely N-end rule substrate.
Mm RIPK1 SLQHD CVPL...S321 656
DLEVD CYRA...A152 409Mm TRAF1 Proapoptotic fragment, generated by caspase-8, of TRAF1,a regulator of apoptosis. Cys-TRAF1 is an N-end rule substrate. 
Mm EPHA4  RVLED D 986769 PEA...V Proapoptotic fragment, generated by caspase-3, of the dependence receptor EPHA4. Cys-EPHA4 is an N-end rule substrate. 
Hs PKCδ  EDMQD N 676325 SGT...D
Hs PKCθ LDEVD K 706350 MCH...S
Hs ETK  EDFPD W 675236 WQV...H
Mm SLK PDTQD QQTV...S1202432
Hs HPK1 YDDVD IPTP...L833381
Mm BRCA1 DDLLD DVEI...D18121118
Mm BIM EL SSECD REGG...H1969
Hs-MLH1 EDKTD IISS...C756414
SWHLA DSPA...K23356
Hs-BID HSRLG RIEA...D19566
Proapoptotic fragment, generated by caspase-3, of the mismatch 
repair protein MLH1. Ile-MLH1 is a likely N-end rule substrate.
Proapoptotic fragment, generated by caspase-3, of the tumor
suppressor BRCA1. Asp-BRCA1 is an N-end rule substrate.
Proapoptotic fragment, generated by caspase-3, of the antiapoptotic  
protein kinase Cθ. Lys-PKCθ is a likely N-end rule substrate.
NdpMm MET NESVD Y 1379996 RAT...S Proapoptotic fragment, generated by caspase-3, of the dependence receptor MET. Tyr-MET is an N-end rule substrate. 
Proapoptotic fragment, generated by caspase-3, of the antiapoptotic 
ETK/BMX tyrosine kinase. Trp-ETK is a likely N-end rule substrate. 
Proapoptotic fragment, generated by calpains, of BID, a regulator
of apoptosis. Arg-BID is an N-end rule substrate. 
Proapoptotic fragment, generated by caspase-3, of the SLK kinase, 
a regulator of actin. Gln-SLK is a likely N-end rule substrate.
Proapoptotic fragment, generated by caspase-3, of the Ser/Thr
kinase HPK1. Ile-HPK1 is a likely N-end rule substrate.
Proapoptotic fragment, generated by caspase-3, of the apoptosis
regulator BIM   . Arg-BIM    is an N-end rule substrate. EL EL
Ndt
Ndp
Ndt
Ndp
Hs NEDD9 MDDYD YVHL...F834626 Proapoptotic fragment, generated by caspase-3, of NEDD9, aregulator of cell adhesion. Tyr-NEDD9 is an N-end rule substrate. Ndp
Ndp
Ndp
Nds
Ndp
Nds
Hs LIMK1 LDEID LLIQ...D647236 Proapoptotic fragment, generated by caspase-3, of LIMK1, a Ser/Thr protein kinase. Leu-LIMK1 is an N-end rule substrate. Ndp
Mm BCLXL
Proapoptotic fragment, generated by calpains, of the antiapoptotic 
regulator BCL   . Asp-BCL    is an N-end rule substrate. XL XL
Fig. S1. Proapoptotic protein fragments that are experimentally conﬁrmed substrates of the Arg/N-end rule pathway and fragments that remain to be
veriﬁed as such. The name of a protein on the left is preceded by the acronym of a species (Hs, Homo sapiens;Mm,Mus musculus). As in the text, the names of
proteins are in all capital letters for both human and mouse proteins. Amino acid residues are indicated by single-letter abbreviations. Arrowheads and the
enlarged residue names in red indicate P1′ residues of the cleavage sites (i.e., the N-terminal residues of C-terminal fragments of the cleaved full-length
proteins). Primary, secondary, and tertiary destabilizing N-terminal residues are denoted as Ndp, Nds, and Ndt, respectively (Fig. 1A) (1, 2). If a depicted cleavage
site is one recognized by a caspase (the exceptions, in the present list, are the cleavage sites that yield Asp-BCLXL and Arg-Bid, which are produced by calpains),
the site is underlined. The residue number on the left is of the ﬁrst shown residue of uncleaved protein numbered as in a full-length protein. The number on
the right is of the last residue of a full-length protein. The ﬁrst section of this ﬁgure describes 10 previously identiﬁed proapoptotic protein fragments,
speciﬁcally Cys-RIPK1, Cys-TRAF1, Asp-BRCA1, Leu-LIMK1, Tyr-NEDD9, Arg-BID, Asp-BCLXL, Arg-BIMEL, Asp-EPHA4, and Tyr-MET. They were examined in the
present study and found to be short-lived substrates of the Arg/N-end rule pathway (Figs. 2–4). Descriptions of these conﬁrmed N-end rule substrates are in SI
Results, section I. The second section describes six other previously identiﬁed proapoptotic fragments (all of them are produced by caspases) bearing desta-
bilizing N-terminal residues that can be recognized by the Arg/N-end rule pathway. These fragments are likely N-end rule substrates but remain to be veriﬁed
as such. Asn-PKCδ is the C-terminal fragment of the protein kinase Cδ (PKCδ) that can be generated by (in particular) caspase-3. This fragment bears N-terminal
Asn (an Ndt residue; see above for notations of destabilizing N-terminal residues) and is proapoptotic, in contrast to the full-length PKCδ kinase (3–7). Lys-PKCθ
is the C-terminal fragment of the protein kinase Cθ (PKCθ). This fragment can be generated by (in particular) caspase-3, bears N-terminal Lys (an Ndp residue),
and is proapoptotic, in contrast to the full-length PKCθ kinase (8). Trp-ETK is the C-terminal fragment of the ETK/BMC tyrosine kinase, a member of the Btk/Tek
family of kinases, at least some of which regulate apoptosis. The Trp-ETK fragment can be generated by (in particular) caspase-3, bears N-terminal Trp (an Ndp
residue), and is proapoptotic, in contrast to the full-length ETK kinase (9). Gln-SLK is the C-terminal fragment of SLK, an STE20-related protein kinase that plays
a role in regulation of actin ﬁbers. The Gln-SLK fragment can be generated by (in particular) caspase-3, bears N-terminal Gln (an Ndt residue), and is proa-
poptotic. The concomitantly produced N-terminal fragment of SLK is also proapoptotic (10). Ile–hematopoietic progenitor kinase 1 (HPK1) is the C-terminal
fragment of HPK1, an STE20-related protein kinase with functions that include stimulation of the stress-activated protein kinases SAPKs/JNKs and the NF-κB
transcriptional regulon. The Ile-HPK1 fragment can be generated by (in particular) caspase-3, bears N-terminal Ile (an Ndp residue), and is proapoptotic, in
contrast to the full-length HPK1 kinase (11). Ile-MLH1 is the C-terminal fragment of the mismatch repair MLH1 protein that can be generated by (in particular)
caspase-3, bears N-terminal Ile (an Ndp residue) resides in the cytosol (unlike the full-length nuclear MLH1), and is proapoptotic, in contrast to full-length MLH1 (12).
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Fig. S2. Evolutionary conservation of the cleavage sites and destabilizing P1′ residues in the proapoptotic protein fragments Cys-RIPK1 (A), Cys-TRAF1 (B), Asp-
BRCA1 (C), Leu-BID (D), Tyr-NEDD9 (E), Leu-LIMK1 (F), Asp-BCLXL (G), Arg-BIMEL (H), Asp-EPHA4 (I), and Tyr-MET (J). These fragments have been shown, in the
present work, to be short-lived N-end rule substrates (Figs. 2 and 3). Except for Arg-BID and Asp-BCLXL ((which are produced from full-length BID by calpains),
these proapoptotic fragments are generated by caspases. Caspase cleavage sites are framed by rectangles and indicated by arrowheads. The indicated residue
numbers, including the numbers of P1′ residues (shown in red), are of the human versions of the cited proteins. Approximate locations and names of speciﬁc
protein domains are indicated as well. These fragments are described in SI Results, section I.
Piatkov et al. www.pnas.org/cgi/content/short/1207786109 9 of 15
1    2    3    4    5 6 7    8    9    10    11 12 13    14    15    16
human T-REx-293 cells
vector Cys
0 804020chase (min): 
N-terminus:
0 8040200 8040200 804020
Asp Val
A
X-hRIPK1f *
*
X-hRIPK1f
B
%
 re
m
a i
ni
n g
1
10
100
0 40 80
chase (min)
Cys-RIPK1
Val-RIPK1
Asp-RIPK1
0
20
40
60
80
100
0 0.2 0.4 0.6 0.8 1.0
staurosporine (μM)
%
 T
U
N
E
L-
po
si
tiv
e 
ce
lls
Ate1 primary EF cells+/+
Ate1 -/- primary EF cells
C
1    2    3    4    5 6
Mm RIPK1
10 0.04 0.2TNFα (ng/ml): 5 25
Ate1-containing 
EF cells
Ate1-deficient 
EF cells
D
E
cycloheximide (2.5 μg/ml)
Mm RIPK1
-RIPK1Cys326
Fig. S3. In vivo degradation of X-RIPK1 fragments and apoptosis hypersensitivity of Ate1−/− cells. (A) 35S–pulse-chase assays with human T-Rex-293–based cell
lines that stably expressed human X325-RIPK1f proteins (x = Cys, Asp, Val) produced from the corresponding Ub-X325-RIPK1f fusions (1, 2). Expression of X-RIPK1f
was induced by Dox (0.1 μg/mL for 24 h). Cells were labeled at 37 °C for 10 min with [35S]methionine/cysteine followed by a chase for 20, 40, and 80 min,
immunoprecipitation of cell extracts with a monoclonal antibody to a C-terminal region of RIPK1, SDS/PAGE, autoradiography, and quantiﬁcation (SI Materials
and Methods). Lanes 1–4 show cells with integrated vector alone (negative control). **Proteins that cross-reacted with anti-RIPK1 antibody. Lanes 5–8 show
Cys-RIPK1f. Lanes 9–12 show Asp-RIPK1f. Lanes 13–16 show Val-RIPK1f. Of the two closely spaced bands of X-RIPK1f in T-Rex-293 cells, the faster-migrating one
was predominant immediately after the pulse, suggesting that the upper band of X-RIPK1f was a modiﬁed (e.g., phosphorylated) derivative of the slower
migrating species. (B) Quantiﬁcation of data in A.◆, Cys-RIPK1;▲, Asp-RIPK1;■, Val-RIPK1. In this quantiﬁcation, the zero-point levels of each of the X-RIPK1
proteins were normalized to 100%. Note that this way of plotting the data omits the additional evidence for metabolic instability of Cys-RIPK1 and Asp-RIPK1
compared with Val-RIPK1. Speciﬁcally, the absolute levels of labeled Val-RIPK1 (A, lanes 13–16) were considerably higher compared with the levels of labeled
Cys-RIPK1 and Asp-RIPK1 (lanes 5–12), reﬂecting a signiﬁcant degradation of Cys-RIPK1 and Asp-RIPK1 before chase (during pulse) in contrast to Val-RIPK1. (C)
Induction of apoptosis by staurosporine in primary (precrisis) WT (◆) and Ate1−/− (■) mouse EF cells. Cultures of primary EFs, derived from either WT or Ate1−/−
mouse E13.5 embryos (3), were treated with increasing concentrations of staurosporine for 24 h followed by TUNEL measurements of the frequency of ap-
optotic cells. SDs are indicated (SI Materials and Methods). (D and E) ATE1-containing (Ate1ﬂox/-) mouse primary EF cells were treated either with (D) DMSO (the
solvent for tamoxifen) alone or (E) tamoxifen in DMSO (50 ng/mL) for 5 d to transiently activate the Cre recombinase in tamoxifen-treated cells, thereby
deleting the remaining copy of Ate1 in these cells (4). Both (D) control (Ate1ﬂox/-) and (E) experimental (Ate1−/−) cell cultures were grown for another 7 d
before treatments for 24 h with increasing concentrations of TNFα in DMEM that also contained 0.5% FBS and a nontoxic (2.5 μg/mL) concentration of cy-
cloheximide followed by SDS/PAGE of cell extracts and immunoblotting with a monoclonal antibody to a C-terminal region of RIPK1. At 5 ng/mL and higher
concentrations of TNFα, ATE1-deﬁcient apoptotic EF cells but not ATE1-containing cells contained readily detectable levels of a RIPK1 fragment that migrated
at the Mr of the 41-kDa Cys
326-RIPK1 fragment (red arrow).
1. Varshavsky A (2005) Ubiquitin fusion technique and related methods. Methods Enzymol 399:777–799.
2. Varshavsky A (2011) The N-end rule pathway and regulation by proteolysis. Protein Sci 20:1298–1345.
3. Kwon YT, et al. (2002) An essential role of N-terminal arginylation in cardiovascular development. Science 297:96–99.
4. Brower CS, Varshavsky A (2009) Ablation of arginylation in the mouse N-end rule pathway: Loss of fat, higher metabolic rate, damaged spermatogenesis, and neurological
perturbations. PLoS One 4:e7757.
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Fig. S4. Effects of TNFα on the levels of RIPK1 in ATE1-containing and -deﬁcient mice and apoptosis hypersensitivity of ATE1-deﬁcient mouse tissues; 3 wk
after tamoxifen-mediated induction of Cre recombinase to ablate the remaining functional copy of the Ate1 gene in Ate1ﬂox/- mice (1), TNFα (50 μg/kg) was
administered by tail vein injection. Control mice were injected with buffer alone. After 12 h, the indicated mouse tissues were harvested, and proteins in tissue
extracts were analyzed by SDS/PAGE and immunoblotting with a monoclonal antibody to a C-terminal region of RIPK1, and also an antibody to β-tubulin
(loading control). (A) Anti-RIPK1 immunoblots of proteins from lungs, spleens, and pancreases of three separate ATE1-containing and three separate ATE1-
deﬁcient mice that were either untreated or treated with TNFα (each lane corresponds to a sample from an individual mouse). Note the virtual disappearance
of full-length RIPK1 from lungs and pancreases of TNFα-treated ATE1-deﬁcient mice (in contrast to ATE1-containing mice) and a similar but less striking pattern
in spleens. Note also a signiﬁcant decrease of the relative tubulin content in samples from pancreases (but not in samples from lungs or spleens) of TNFα-
treated ATE1-deﬁcient mice, in contrast to ATE1-containing mice. These tubulin patterns were consistent with cytological signs of damage to acinar pancreatic
cells of TNFα-treated ATE1-deﬁcient (but not ATE1-containing) mice, and they were in agreement with the observed toxicity of TNFα to ATE1-deﬁcient mice.
Lanes 19 and 20, same as lanes 17 and 18, respectively, but a longer immunoblotting exposure that revealed a RIPK1 fragment (indicated by the arrowhead)
that migrated at the Mr of the 41-kDa Cys
326-RIPK1 fragment (in the text). (B) ATE1-deﬁcient mouse organs are hypersensitive to apoptosis. Representative
images of 10-μm sections of lungs and pancreases from ATE1-containing and -deﬁcient mice (1) that were treated for 12 h with TNFα. The sections were
processed using the ﬂuorescein-based TUNEL assay for apoptotic cells and staining with DAPI to visualize cell nuclei. (Scale bars, 100 μm.) A shows immu-
noblotting analyses of RIPK1 and Fig. 1E shows quantiﬁcation of these data.
1. Brower CS, Varshavsky A (2009) Ablation of arginylation in the mouse N-end rule pathway: Loss of fat, higher metabolic rate, damaged spermatogenesis, and neurological
perturbations. PLoS One 4:e7757.
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Fig. S5. Nt-arginylation under condition of apoptosis induction and caspase-mediated cleavages of ATE1 and UBR1. (A) In vitro Nt-arginylation assay with
extracts from mouse NIH-3T3 cells supplemented, in particular, with Glu-lactalbumin (Nt-arginylation reporter) and L-3H-arginine. Cells were treated as de-
scribed below, followed by measurements of Nt-arginylation activity in cell extracts. ○, treatment with buffer alone;■, TNFα (50 ng/mL);▲, cycloheximide (10
μg/mL); ●, TNFα (50 ng/mL) and cycloheximide (10 μg/mL) together. (B) Extracts from 3T3 cells treated with TNFα and cycloheximide as described in A were
fractionated by SDS/PAGE followed by immunoblotting with afﬁnity-puriﬁed antibody to mouse ATE1, a monoclonal antibody to a C-terminal region RIPK1,
and antibody to tubulin. (C) The mouse ATE1 R-transferase and the evolutionary conservation of its putative caspase-8/caspase-3 cleavage sites are framed by
rectangles and indicated by arrowheads. A conserved destabilizing P1′ residue (Leu) at one of the cleavage sites is marked in red. The residue numbers shown
are for the Ate11B7A isoform (1, 2). Both the 200-kDa mouse UBR1 E3 N-recognin and other E3 N-recognins (UBR2, UBR4, and UBR5) (Fig. 1A) also contain
putative caspase-8/caspase-3 cleavage sites. (D) N-terminally His10-tagged mouse Ate1
1B7A was expressed in E. coli and puriﬁed by Ni2+ afﬁnity chromatog-
raphy; 1 μg ATE1 was incubated in caspase assay buffer in a total volume of 20 μL either in the absence of added caspase-8 (lane 1) or with the indicated
(decreasing) amounts of the recombinant human caspase-8 (lanes 2–8), followed by SDS/PAGE and immunoblotting with afﬁnity-puriﬁed anti-ATE1 antibody.
Fig. 4B shows direct evidence that caspase-8 can functionally inactivate the ATE1 R-transferase. (E) Extracts from mouse NIH 3T3 cells (lanes 1–3) or Ubr1−/−
Ubr2−/− double-mutant mouse EF cells (2–4) that lacked the UBR1 and UBR2 N-recognins (lane 4; a control for speciﬁcity of anti-UBR1 antibody) were incubated
in either (lanes 1 and 4) absence of added caspase-8 or (lanes 2 and 3) with recombinant caspase-8 (10 μg/mL), followed by SDS/PAGE and immunoblotting with
antibody to mouse UBR1 (5). Z-VAD-FMK, a pan-caspase inhibitor, was added to the assay of lane 3. Two caspase-produced UBR1 fragments, the ∼180-kDa
fragment-1 and the ∼130-kDa fragment-2, are indicated.
1. Hu R-G, et al. (2006) Arginyltransferase, its speciﬁcity, putative substrates, bidirectional promoter, and splicing-derived isoforms. J Biol Chem 281:32559–32573.
2. Varshavsky A (2011) The N-end rule pathway and regulation by proteolysis. Protein Sci 20:1298–1345.
3. Tasaki T, et al. (2005) A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons. Mol Cell Biol 25:7120–7136.
4. An JY, et al. (2006) Impaired neurogenesis and cardiovascular development in mice lacking the E3 ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway. Proc Natl Acad Sci USA
103:6212–6217.
5. Kwon YT, Xia Z, Davydov IV, Lecker SH, Varshavsky A (2001) Construction and analysis of mouse strains lacking the ubiquitin ligase UBR1 (E3alpha) of the N-end rule pathway.Mol Cell
Biol 21:8007–8021.
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Table S1. Plasmids used in this study
Plasmid Description Source or reference
pcDNA3.1-Neo AmpR; NeoR; Expression vector for cloning your gene of interest Invitrogen
pcDNA5/FRT/TO AmpR; Tetracycline inducible expression vector for cloning your gene of interest Invitrogen
pOG44 AmpR; Vector for transient expression of the Flp recombinase Invitrogen
IMAGE clone: 30748947 AmpR; full-length mouse TRAF1 cDNA Open Biosystems
IMAGE clone: 6512978 AmpR; full-length mouse EPHA4 cDNA Open Biosystems
IMAGE clone: 40098362 AmpR; 3′ fragment of mouse MET cDNA Open Biosystems
Clone: LIFESEQ95191844 AmpR; full-length human LIMK1 cDNA Open Biosystems
Clone: 6830063 AmpR; full-length mouse BCLXL cDNA Open Biosystems
Clone: 4459720 AmpR; mouse BIMEL cDNA Open Biosystems
Clone: 30431022 AmpR; full-length mouse mBRCA1 cDNA Open Biosystems
Clone: 5179075 AmpR; full-length human BID cDNA Open Biosystems
Clone: 6299616 CmR; human NEDD9 cDNA Open Biosystems
pKP378 AmpR; NeoR; pcDNA3.0-based plasmid encoding full-length mTRAF1-ﬂag
under the control of CMV promoter
This study
pKP379 AmpR; NeoR; pcDNA3.0-based plasmid encoding full-length mTRAF1 (D156A)-ﬂag
under the control of CMV promoter
This study
pKP380 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-Ub-Сys157-mTRAF1-ﬂag under
the control of CMV promoter
This study
pKP381 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-Ub-Met157-mTRAF1-ﬂag under
the control of CMV promoter
This study
pKP382 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-Ub-Asp157-mTRAF1-ﬂag under
the control of CMV promoter
This study
pKP393 AmpR; NeoR; pcDNA3.0-based plasmid encoding full-length mRIPK1-ha2 under the
control of CMV promoter
This study
pKP394 AmpR; NeoR; pcDNA3.0-based plasmid encoding full-length hRIPK1-ha2 under the
control of CMV promoter
This study
pKP395 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha-Ub-Cys326-mRIPK1-ha2-ﬂag
under the control of CMV promoter
This study
pKP396 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Asp326-mRIPK1-ha2-ﬂag
under the control of CMV promoter
This study
pKP397 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha-Ub-Val326-mRIPK1-ha2-ﬂag
under the control of CMV promoter
This study
pKP399 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha-Ub-Cys325-hRIPK1-ha2-ﬂag
under the control of CMV promoter
This study
pKP400 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha-Ub-Asp325-hRIPK1-ha2-ﬂag
under the control of CMV promoter
This study
pKP401 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha-Ub-Val325-hRIPK1-ha2-ﬂag
under the control of CMV promoter
This study
pKP409 AmpR, Ura3; p416-Met25-based plasmid encoding ﬂag-DHFR-Ub-Asp326-mRIPK1-ha2-ﬂag
under the control of Met25 promoter
This study
pKP411 AmpR, Ura3; p416-Met25-based plasmid encoding ﬂag-DHFR-Ub-Val326-mRIPK1-ha2-ﬂag
under the control of Met25 promoter
This study
pKP418 AmpR; HygR; pcDNA5/FRT/TO-based plasmid encoding Ub-Cys325-hRIPK1-ha2-ﬂag under
the control of Tet promoter
This study
pKP419 AmpR; HygR; pcDNA5/FRT/TO-based plasmid encoding Ub-Asp325-hRIPK1-ha2-ﬂag under
the control of Tet promoter
This study
pKP420 AmpR; HygR; pcDNA5/FRT/TO-based plasmid encoding Ub-Val325-hRIPK1- ha2-ﬂag under
the control of Tet promoter
This study
pKP492 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha-Ub-Asp774-mEPHA4-ﬂag
under the control of CMV promoter
This study
pKP493 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Val774-mEPHA4-ﬂag
under the control of CMV promoter
This study
pKP496 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-MCS-ﬂag under the
control of CMV promoter; MCS has SacII, EcoRI, XhoI, ClaI, and EcoRV unique cloning sites
This study
pKP512 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Leu241-hLIMK1-ﬂag
under the control of CMV promoter
This study
pKP513 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Val241-hLIMK1-ﬂag
under the control of CMV promoter
This study
pKP514 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Asp61-mBCLXL-ﬂag
under the control of CMV promoter
This study
pKP515 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Val61-mBCLXL-ﬂag
under the control of CMV promoter
This study
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Table S1. Cont.
Plasmid Description Source or reference
pKP519 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Tyr1001-mMET-ﬂag
under the control of CMV promoter
This study
pKP520 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Val1001-mMET-ﬂag
under the control of CMV promoter
This study
pKP521 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Arg14-mBIMEL-ﬂag
under the control of CMV promoter
This study
pKP522 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Val14-mBIMEL-ﬂag
under the control of CMV promoter
This study
pKP523 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Arg71-hBID-ﬂag
under the control of CMV promoter
This study
pKP524 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Val71-hBID-ﬂag
under the control of CMV promoter
This study
pKP526 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Tyr631-Hnedd9-ﬂag
under the control of CMV promoter
This study
pKP527 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Val631-hNEDD9-ﬂag
under the control of CMV promoter
This study
pKP528 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Asp1119-mBRCA1-ﬂag
under the control of CMV promoter
This study
pKP529 AmpR; NeoR; pcDNA3.0-based plasmid encoding ﬂag-DHFR-ha Ub-Val1119-mBRCA1-ﬂag
under the control of CMV promoter
This study
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Table S2. Primers used in this study
Primer Primer’s sequence
647 TTCTCGAGCTAGGCGTAATCTGGGACATCGTATGGGTAGGAACCTGAGGCGTAATCTGGG
650 AAATAAAGCTTATGCAACCAGACATGTCCTTGG
651 AACCTGAGGCGTAATCTGGGACATCGTAAGGGTAGCTCTGGCTGGCACGAATCA
652 TTTTTAAGCTTATGCAACCAGACATGTCCTTG
653 AACCTGAGGCGTAATCTGGGACATCGTAAGGGTAGTTCTGGCTGACGTAAATCAAGC
697 TTCTCGAGCTAACCTTTGTCGTCATCGTCTTTGTAGTCGGCGTAATCTGGGACATCGTAT
702 TTTTTCCCGGGTGTGTACCCTTACCTCCGAGCAG
703 TTTTTCCCGGGGACGTACCCTTACCTCCGAGCAG
705 TTTTTCCCGGGGTTGTACCCTTACCTCCGAGCAG
707 TTTTTCCCGGGTGTGTGGCAGTACCTTCAAGCC
708 TTTTTCCCGGGGACGTGGCAGTACCTTCAAGCC
709 TTTTTCCCGGGGTTGTGGCAGTACCTTCAAGCC
1,188 CACACGGATCCACCATGGCCTCCAGCTCAGCCCCT
1,189 TTTTTTCTAGATAACCTTTGTCGTCATCGTCTTTGTAGTCAGCACTAGTGTCCACAATGC
1,190 GACCTGGAGGTAGCCTGCTACCGGGC
1,191 GCCCGGTAGCAGGCTACCTCCAGGTC
1,193 CACACGGATCCACCATGAACATTTTCGTCAAGACTTTGACC
1,194 CCCGCCTCTTAGCCTTAGCACA
1,195 TGTGCTAAGGCTAAGAGGCGGGGACTACCGGGCACCTTGCTGT
1,196 TGTGCTAAGGCTAAGAGGCGGGGTTTACCGGGCACCTTGCTGT
1,197 CACACGGATCCACCATGGTTGACTACAAGGACGACGACGACAAGGGA
1,198 AAGGACGACGACGACAAGGGACAGATTTTCGTCAAGACTTTG
1,369 TATAGCCCGGGGACCCCGAAGCAGCCTACACTACC
1,370 TATAGCCCGGGGTTCCCGAAGCAGCCTACACTACC
1,371 TAATTTCTAGATTAACCTTTGTCGTCATCGTCTTTGTAGTCGACAGGAACCATCCTGCCA
1,447 GGGAATTCCTCGAGATCGATATCGACTACAAAGACGATGACGACAAAGGTTAAT
1,448 CTAGATTAACCTTTGTCGTCATCGTCTTTGTAGTCGATATCGATCTCGAGGAATTCCCGC
1,426 AAAAACCGCGGAGGATACAGAGCTACTTTTCCAGAAGACCAGT
1,427 AAAAACCGCGGAGGAGTTAGAGCTACTTTTCCAGAAGACCAGT
1,428 TTTGTATCGATTGTGTTCCCCTCGCCATCA
1,432 AAAAACCGCGGAGGAGATAGCCCGGCCGTGAATGGAGC
1,433 AAAAACCGCGGAGGAGTTAGCCCGGCCGTGAATGGAGC
1,434 TTTTAATCGATCTTCCGACTGAAGAGTGAGCCC
1,435 AAAAACCGCGGAGGAAGAGAAGGTGGACAATTGCAGCCTG
1,436 AAAAACCGCGGAGGAGTTGAAGGTGGACAATTGCAGCCTG
1,437 TTTTAATCGATATGCCTTCTCCATACCAGACGG
1,438 AAAACCGCGGAGGAGATGTTGAAATACAGGGACATACTAGCTT
1,439 AAAACCGCGGAGGAGTTGTTGAAATACAGGGACATACTAGCTT
1,440 TTTTAATCGATATCATTGGAGTCTTGTGGCTCAC
1,467 AAAAACCGCGGAGGACTGCTGATTCAGGAAACCAGCCG
1,468 AAAAACCGCGGAGGAGTTCTGATTCAGGAAACCAGCCG
1,469 TTTTAATCGATGTCGGGGACCTCAGGGTGGGC
1,473 AAAACCGCGGAGGAAGAATAGAGGCAGATTCTGAAAGTCAAG
1,474 AAAACCGCGGAGGAGTTATAGAGGCAGATTCTGAAAGTCAAG
1,475 TTTTAATCGATGTCCATCCCATTTCTGGCTAAGC
1,479 AAAAACCGCGGAGGATACGTCCACCTACAGGGTAAGGAGGAGT
1,480 AAAAACCGCGGAGGAGTTGTCCACCTACAGGGTAAGGAGGAGT
1,481 TTTTAATCGATGAACGTGGCCATCTCCAGCAAAGAG
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